Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price shot up 42.9% during trading on Tuesday . The stock traded as high as C$0.11 and last traded at C$0.10. 370,639 shares were traded during mid-day trading, an increase of 290% from the average session volume of 95,035 shares. The stock had previously closed at C$0.07.
Hemostemix Stock Up 71.4 %
The firm has a market cap of C$10.45 million, a PE ratio of -6.00 and a beta of 0.20. The business has a 50-day moving average price of C$0.08 and a two-hundred day moving average price of C$0.07.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Recommended Stories
- Five stocks we like better than Hemostemix
- Bank Stocks – Best Bank Stocks to Invest In
- Analysts’ Favorite Cybersecurity Stocks: 3 Top Picks
- Conference Calls and Individual Investors
- Analysts Are Bullish: 3 Tech Giants With Upgraded Price Targets
- How to buy stock: A step-by-step guide for beginners
- These 3 Retail Stocks Can Keep Winning in 2025
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
